MARKET

SNDX

SNDX

Syndax Pharmaceuticals Inc
NASDAQ
23.24
+1.16
+5.25%
Pre Market: 23.00 -0.24 -1.03% 05:07 07/08 EDT
OPEN
22.38
PREV CLOSE
22.08
HIGH
23.47
LOW
22.04
VOLUME
200
TURNOVER
0
52 WEEK HIGH
25.59
52 WEEK LOW
8.59
MARKET CAP
2.06B
P/E (TTM)
-8.3024
1D
5D
1M
3M
1Y
5Y
1D
Why Syndax Pharmaceuticals (SNDX) Is Up 6.3% After Broad Russell Value Index Removal And What's Next
Simply Wall St · 5h ago
Weekly Report: what happened at SNDX last week (0629-0703)?
Weekly Report · 2d ago
Syndax Pharmaceuticals (SNDX) Reports Strong Revuforj Data, Is The Upside Already Priced In?
Simply Wall St · 3d ago
Syndax grants stock option inducement awards for 250,700 shares to eight new employees
PUBT · 6d ago
SYNDAX PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 6d ago
Weekly Report: what happened at SNDX last week (0622-0626)?
Weekly Report · 06/29 09:50
Does Syndax Pharmaceuticals’ (SNDX) Russell Value Index Exit Quietly Recast Its Liquidity And Risk Narrative?
Simply Wall St · 06/29 03:22
Jazz Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade)
Seeking Alpha · 06/26 13:22
More
About SNDX
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

Webull offers Syndax Pharmaceuticals Inc stock information, including NASDAQ: SNDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNDX stock methods without spending real money on the virtual paper trading platform.